Key Documents

View All Documentation

B0470000

Benperidol

Name: Benperidol
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-{1-[4-(4-Fluorophenyl)-4-oxobutyl]-piperidin-4-yl}-1,3-dihydro-benzimidazol-2-one

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₄FN₃O₂

CAS Number:

2062-84-2

Molecular Weight:

381.44

MDL number:

MFCD00866672

UNSPSC Code:

41116107

NACRES:

NA.24

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

benperidol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Fc1ccc(cc1)C(=O)CCCN2CCC(CC2)[n]3c4c([nH][c]3=O)cccc4

InChI

1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)

InChI key

FEBOTPHFXYHVPL-UHFFFAOYSA-N

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Benperidol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Leukopenia associated with butyrophenones. A successful treatment of psychoses with pulsed administration of neuroleptics].

M Grube et al.

Der Nervenarzt, 70(9), 838-841 (1999-10-16)

In the monotherapeutic treatment of an acute schizophrenic psychoses with butyrophenones (haloperidol and benperidol) we saw immediate leucopenic reactions when the medication was given every day. In literature the risk of butyrophenone-induced blood dyscrasias seems to be underestimated. Therefore we

Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.

Andreas Bender et al.

ChemMedChem, 2(6), 861-873 (2007-05-05)

Preclinical Safety Pharmacology (PSP) attempts to anticipate adverse drug reactions (ADRs) during early phases of drug discovery by testing compounds in simple, in vitro binding assays (that is, preclinical profiling). The selection of PSP targets is based largely on circumstantial

Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.

M Jauss et al.

Movement disorders : official journal of the Movement Disorder Society, 11(6), 726-728 (1996-11-01)

With the tracer [123I]iodobenzamide ([123I]-IBZM), it is possible to image dopamine receptor occupancy with single-photon emission-computed tomography (SPECT). We report follow-up examinations with IBZM-SPECT in neuroleptic malignant syndrome (NMS) to display D2-receptor availability in the acute phase and during the

View All Related Papers

Global Trade Item Number

SKU	GTIN
B0470000	04061833799314